advexin

Known as: INGN 201, INGN-201, RPR/INGN-201 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2015
02420012015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Multimodal approaches combining drugs that differentially function is the most popular regimen for treating human cancer… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2009
Review
2009
Contusugene ladenovec (Advexin; INGN-201; Introgen Therapeutics Inc) is a replication-impaired, non-integrating, serotype 5… (More)
Is this relevant?
Review
2008
Review
2008
Li-Fraumeni syndrome is a rare autosomal dominant cancer predisposition syndrome. The majority of families fulfilling definition… (More)
Is this relevant?
Review
2008
Review
2008
As gene therapy has matured from clinical trials to the first commercial products, understanding of the mechanisms of gene… (More)
Is this relevant?
2007
2007
Li-Fraumeni syndrome is an autosomal dominant disorder that greatly increases the risk of developing multiple types of cancer… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2006
2006
We investigated the feasibility, safety, biological activity and therapeutic efficacy of adenovirus-mediated p53 gene transfer in… (More)
Is this relevant?
Review
2006
Review
2006
Mutations in the p53 gene are the most frequent genetic alterations in human tumours, occurring in approximately 50% of all… (More)
Is this relevant?
2006
2006
The first gene-therapy treatment to enter the market should have received a tremendous reception, but the fact that it was… (More)
  • figure 1
  • figure 2
Is this relevant?
Review
2004
Review
2004
PURPOSE Adenoviral p53 (Adp53) is a replication-deficient adenovirus containing human p53 cDNA. This phase I study was designed… (More)
Is this relevant?
Review
2001
Review
2001
In April 2001, Aventis and Introgen signed a letter of intent to restructure their collaboration arrangement, giving Introgen… (More)
Is this relevant?